Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer - PubMed
3 days ago
- #NSCLC
- #antibody-drug conjugates
- #targeted therapy
- Lung cancer is the leading cause of cancer-related deaths, with NSCLC being the most common type.
- Current treatments like chemotherapy and monoclonal antibodies have limitations in efficacy and toxicity.
- Antibody-drug conjugates (ADCs) combine tumor-targeting antibodies with cytotoxic agents to improve treatment.
- ADCs target specific markers like HER2, TROP2, c-MET, HER3, CEACAM5, and B7-H3 in NSCLC.
- Clinical challenges include tumor heterogeneity, resistance, and biomarker variability.
- Emerging ADC strategies include next-gen designs, novel linkers, and combination therapies.
- ADCs show promise in improving outcomes for advanced NSCLC patients.